Lines and crackles. Making sense of ILD

Similar documents
INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

Diagnostic challenges in IPF

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None

CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

Non-neoplastic Lung Disease II

A Review of Interstitial Lung Diseases

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

Case 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

DIAGNOSTIC NOTE TEMPLATE

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

Manish Powari Regional Training Day 10/12/2014

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Epidemiology and classification of smoking related interstitial lung diseases

Differential diagnosis

Liebow and Carrington's original classification of IIP

CTD-related Lung Disease

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.

HRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution

Progress in Idiopathic Pulmonary Fibrosis

Unpaid scientific collaborator & advisor with Veracyte, Inc.

Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

COI: no conflicts of interest to declare

Acute and Chronic Lung Disease

IPF: Epidemiologia e stato dell arte

Diagnosing ILD. What is important in 2016? Chris Grainge

International consensus statement on idiopathic pulmonary fibrosis

Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Prague, June 2014

Bill Davies PAC RRT. Dyspnea: Uncovering Restrictive lung Disorders in Your Setting

HYPERSENSITIVITY PNEUMONITIS

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

PNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT. Carlos Robalo Cordeiro

Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

Daria Manos RSNA 2016 RC tment-sites/radiology/contact/faculty/dariamanos.html

Case 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule

Interstitial Lung Disease

Dr.kassim.m.sultan F.R.C.P

Interstitial Lung Disease

Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page

IPF - Inquadramento clinico

Hypersensitivity Pneumonitis: Epidemiology and Classification

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

Multidisciplinary Diagnosis in Action: Challenging Case Presentations

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?

Summary: Key Learning Points, Clinical Strategies, and Future Directions

ESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule

I have no relevant conflicts of interest to disclose

UIP Possibile e Probabile

Histopathologic Approach to Interstitial Lung Disease

The radiological differential diagnosis of the UIP pattern

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Case Study #2. Case Study #1 cont 9/28/2011. CAPA 2011 Christy Wilson PA C. LH is 78 yowf with PMHx of metz breast CA presents

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)

Restrictive lung diseases

Guidelines for Diagnosis and Treatment of IPF

Definition, classification and epidemiology

Smoking-related Interstitial Lung Diseases: High-Resolution CT Findings

Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary of Care

The ABC s of ILD LIP AIP NSIP

Timely Topics in Pulmonary Medicine

C h a p t e r 1 3 Interstitial Lung Disease

Chest imaging II. Interstitial lung diseases

Interstitial Lung Disease ILD: Definition

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

LUNG DISEASES DUE TO ORGANIC&INORGANIC DUSTS. Dr.kassim.m.sultan F.R.C.P

NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease (ILD)

Challenges in Pulmonary and Critical Care: 2018

Radiologic Approach to Smoking Related Interstitial Lung Disease

Pulmonary Test Brenda Shinar

Déjà vu all over again

UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!

BRONCHOALVEOLAR LAVAGE (BAL) Venerino Poletti Osp GB Morgagni, Forlì (I)

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar

Colorado Pharmacists Society Annual Meeting June 21 st & 22 nd, 2018

Professor Rob Miller

V CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE

Transcription:

Lines and crackles Making sense of ILD

Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to Cardiology, they felt not heart, must be lungs

Intro to ILD Over 200 causes/diseases Distribution worldwide Prevalence increasing Median survival of IPF 3-5 years History is crucial Most present with progressive dyspnea and dry cough and abnormal CXR/CT New meds available for IPF/UIP

General causes of ILD Infection: viral, bacterial, fungal, PCP Dusts Drugs Radiation CTD Sarcoid CHF Lymphangitic spread of cancer COP HP

ILD cause in the US 20% IPF 20% CTD-ILD 20% Chronic HP 20% Sarcoidosis 10% Pneumoconioses 10% Other ILD Lederer, NEJM 2018

ILD history taking Occupational hx Connective tissue disease symptoms Drugs Family history Environmental exposures: hypersensitivity pneumonitis Radiation

Occupational lung disease HISTORY! Silicosis Asbestosis Talcosis Berylliosis Coal worker s pneumoconiosis Hard metal disease

Connective tissue diseases SLE RA PSS DM/PM AS MCTD Vasculitides

Drugs causes of ILD Nitrofurantoin Cyclophosphamide Methotrexate Rituximab (Rituxan) Bleomycin Amiodarone

Hypersensitivity pneumonitis Extrinsic allergic alveolitis Farmer s lung Bird fancier s lung Hot tub lung (MAC) Bagassosis Paprika slicer s lung Mummy handler s lung

Case JM No clear occupational risks No radiation or drugs that would suggest cause Possible family history: uncle that died of some lung problem No history that would suggest a HP Exam: mild clubbing suggested Exam: fine crackles in the bases Remainder of exam normal

Examination in ILD Skin: signs of CTD CV: cor pulmonale Lungs: fine crackles MS: signs of CTD

CTD causes of ILD

Clubbing

Finger clubbing

Diffenterial diagnosis of clubbing Lung cancer ILD Asbestosis TB Cyanotic heart disease IBD Cystic fibrosis Bronchiectasis

Fine crackles

Fine crackles ILD CHF Pneumonia Bronchiectasis Atelectasis

Radiology in ILD Get the old CXRs! Reticular Nodular Mixed Most will need High Resolution CT

Case JM After exam and CXR now suspect some type of ILD CT chest: high resolution/thin section Pulmonary function studies: spirometry/static lung volumes/dlco Laboratory: ANA, RA

Radiology

Honeycomb lung

Differential diagnosis for honeycomb lung IPF/UIP NSIP Hypersensitivity pneumonitis Sarcoidosis Bleomycin/methotrexate Langerhans cell histiocytosis Asbestosis

UIP CT scan definitions HRCT must be done according to criteria Definite: Subpleural basal predominance Reticular abnormality Honeycomb +/- traction bronchiectasis Absent of features inconsistent with UIP

Pulmonary function tests Flow volume loop: restrictive/no bronchodilator response Total lung capacity: low Diffusion capacity: low

Laboratory CBC UA Liver enzymes, BUN, Creatinine CPK ANA RA titer HP testing ACE level?

Biomarkers Matrix metalloproteinase 1 & 7 YKL-40 Osteopontin S100A9 in BAL fluid Kerbs von Lungren (KL)-6

Cardiac evaluation EKG BNP Echo

Case JM PFT s show restrictive mechanics and low DLCO Now have CT evidence of pulmonary fibrosis Lab: RA negative ANA 1:40 No clear reason for these findings Now suspect Idiopathic Pulmonary Fibrosis-IPF Next step: tissue or not?

Bronchoscopy in workup of ILD BAL: mainly to rule out infection Cell types not often done in US TBB: sarcoid, cancer, COP Problems are crush artifact and small specimens Transbronchial cryo lung biopsy

TBCLB Transbronchial cryo lung biopsy Yield 74-80% Bigger pieces Less crush artifact?safety: pneumo/bleeding Same day Less anesthesia

Surgical lung biopsy Gold standard 2-4 days in the hospital 3-4% mortality Complications 16% Air leak, ex ILD, bleeding, delayed wound healing 57% of patients still have pain at incision site 6-12 months post op

Pathogenesis Repetitive alveolar injury Aberrant wound healing Fibroblast proliferation Expansion of extracellular matrix Loss of normal lung architecture Environmental exposure to genetically susceptible individuals

Usual interstitial pneumonia Classic IPF or Pulmonary Fibrosis Pathology in asbestosis Also advanced HP, RA, drugs, PSS

Non-specific interstitial pneumonia Most common pathology in CTD Subacute setting, fever More treatable than UIP

Desquamative interstitial pneumonia Smokers Less than 10% of all idiopathic ILD pts Ground glass in CT scan Occasional seen in CTD Lots of macrophages Steroid responsive 80% live 10 years or more

Respiratory bronchiolitis-ild Smokers 2% of idiopathic ILD patients 40-50 years old Mild symptoms More common in males Smoking cessation

Acute interstitial pneumonia ARDS without a cause Acute, rapidly progressive On pathology Diffuse Alveolar Damage No treatment High mortality

Pathology

IPF Progressive Rate of progression variable 50% five year survival 60-70 years old on presentation More common in males UIP cell type Now two medications for this disease

Co-morbidities in IPF Pulmonary hypertension: 30-50% poorer prognosis Lung cancer: 7 times general population COPD/emphysema: normal flow rates, low DLCO GERD: cause and exacerbations VTE CAD: second leading cause of death King, Lancet Respir 2017

Case JM Decided did not need biopsy Diagnosis: IPF/UIP Now discussion on therapy Medications over $100K per year!

Pirfenidone (Esbriet) Inhibits transforming growth factor beta Slowed the reduction in the FVC GI issues, liver enzymes, rash Titration difficult: lots of pills 267 mg dose caps/tabs 1 three times a day, then 2 three times a day, then 3 three times a day 801 mg tablet available

Nintedanib (Ofev) Tyrosine kinase blocker Slowed the reduction in the FVC Liver, GI issues Dosing easier 150 mg BID 100 mg pill available

Adjunct therapies Pulmonary Rehabilitation: improved symptoms, if transplant candidate will likely be required Smoking cessation Education Treat GERD: 90% have it? Vaccines Oxygen: treat if hypoxemia, not good data Palliative care

Lung transplantation Consider referral early 1,000 per year in US for ILD Fibrosis does not recur in the transplanted lung One year survival 74-84% Five year survival 40-50%

Multidisciplinary team Pulmonary Radiology Pathology Rheumatology GI? Cardiology?

Summary Think of it! Dyspnea, crackles, dry cough, abnormal CXR Extensive history for CTD, occupations, medications Ok to get the HRCT if suspected Likely will refer for confirmation and treatment

References Martinez, Lancet Respir 2017 King, Lancet Respir 2017e Mikolasch et al, Clin Med 2016 Adegunsoye, Chest 2016 Raghu et al, AJRCCM 2015 Lederer and Martinez, NEJM 2018